| Therapeutic | Gevokizumab |
| Target | IL1B |
| Heavy Chain | QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS |
| Light Chain | DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK |
| 100% seqID Fv Structure | 4g6k%3AHL%2F4g6m%3AHL [Fvs: ] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4g6k%3AHL%2F4g6m%3AHL [Fvs: ] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (August '23) | Phase-III |
| Estimated Status (August '23) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2010 |
| INN Year Recommended | 2011 |
| Companies Involved | IRIS%3BNational Eye Institute%3BNorth Shore-Long Island Jewish Health System%3BNovartis%3BServier%3BUniversity of Zurich%3BXOMA |
| Conditions Approved | na |
| Conditions Active | Uveitis%3BAcne vulgaris%3BAcute coronary syndromes%3BDiabetic nephropathies%3BGiant cell arteritis%3BLabyrinthitis%3BMyositis%3BOsteoarthritis%3BSchnitzler syndrome%3BScleritis%3BColorectal cancer%3BRenal cell carcinoma |
| Conditions Discontinued | Rheumatoid arthritis%3BCancer%3BGout%3BJuvenile rheumatoid arthritis%3BType 1 diabetes mellitus%3BType 2 diabetes mellitus%3BPyoderma |
| Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]
